Tonix Pharmaceuticals Holding Corp (TNXP) - News Archive

Tonix Pharmaceuticals Tonmya Granted Fast Track Designation by FDA for Fibromyalgia TreatmentFibromyalgia, a chronic disorder characterized by widespread musculoskeletal pain, fatigue, and sleep disturbances, affects ap...

CHATHAM, N.J., July 09, 2024 - Tonix Pharmaceuticals Holding Corp (Nasdaq: TNXP), a well-established biopharmaceutical company that focuses on integrated research and development, revealed today that it has entered into...

Tonix Pharmaceuticals Awarded $34 Million U.S. Department of Defense Contract for Rapid Development of Broad-Spectrum Antiviral ProgramIn a major achievement, Tonix Pharmaceuticals has been granted a defense contract by...

Tonix Pharmaceuticals Holding Corp, a leading biopharmaceutical company, has announced the successful completion of its public offering, with impressive results. The offering included both common stock and pre-funded wa...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has recently made an exciting announcement regarding its plans for a public offering. The biopharmaceutical company has entered into a placement agency agreement to off...

Tonix Pharmaceuticals Regains Compliance with Nasdaq Listing RequirementsCHATHAM, N.J., June 26, 2024 - Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a leading biopharmaceutical company, has recently announced tha...

Tonix Pharmaceuticals, a renowned pharmaceutical company dedicated to improving the lives of patients suffering from chronic pain conditions, recently presented significant data at the Annual Scientific Meeting of the A...

IntroductionTonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) recently concluded a highly successful public offering, solidifying its position as a leading biopharmaceutical company. This strategic move comes at a cruc...

Tonix Pharmaceuticals Executes $4.0 Million Public OfferingCHATHAM, New Jersey, June 12, 2024 Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), an established leader in the biopharmaceutical industry, today announced...

Tonix Pharmaceuticals Holding Corp. Announces Plans to Offer Shares of Common StockChatham, N.J.-based biopharmaceutical company Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) made a significant announcement today r...

Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split: A Promising Move for the Struggling CompanyTonix Pharmaceuticals Holding Corp recently made an announcement that has caught the attention of investors and in...

: This article aims to provide an analysis of the presentations made by Tonix Pharmaceuticals at the American Transplant Congress 2024 regarding the potential of their novel drug, TNX-1500, in preventing rejection in or...

Fibromyalgia is a debilitating condition characterized by chronic pain, fatigue, and cognitive difficulties, commonly referred to as brain fog. The search for an effective treatment has proven challenging, with limited...

Fibromyalgia, a complex chronic pain disorder characterized by widespread musculoskeletal pain and associated symptoms, continues to pose significant challenges for both patients and healthcare providers. The need for e...

Tonix Pharmaceuticals Announces Successful Pricing of $4.4 Million Registered Direct OfferingTonix Pharmaceuticals Holding Corp (Nasdaq: TNXP) has made a significant announcement regarding a registered direct offering w...

Tonix Pharmaceuticals Holding Corp has recently achieved a significant milestone in its mission to develop innovative therapies for pediatric diseases. The company announced that it has been granted the highly coveted R...

The American Chemistry Society (ACS) Spring 2024 Meeting witnessed a groundbreaking announcement by Tonix Pharmaceuticals, unraveling the discovery of novel next-generation oxytocin analogues. This discovery holds immen...

Tonix Pharmaceuticals, a leading biopharmaceutical company, recently announced the selection of two contract manufacturing organizations for the launch and commercial manufacture of Tonmya. Tonmya is an innovative first...

Transitioning to a Fully Integrated Biopharmaceutical Company: The Evolution of Tonix PharmaceuticalsTonix Pharmaceuticals, a renowned pharmaceutical company, has recently announced its transition to a fully integrated...

aims to explore groundbreaking developments in the field of pharmaceutical research. This article highlights the significant findings from the RESILIENT Phase 3 Clinical Trial, conducted by Tonix Pharmaceuticals, regard...